Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
To evaluate the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on weight reduction in patients with Type 2 diabetes mellitus (Type 2 DM), a network meta-analysis was conducted. MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov were searched from 1950 to October 2013....
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2015/157201 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551412366573568 |
|---|---|
| author | Feng Sun Sanbao Chai Lishi Li Kai Yu Zhirong Yang Shanshan Wu Yuan Zhang Linong Ji Siyan Zhan |
| author_facet | Feng Sun Sanbao Chai Lishi Li Kai Yu Zhirong Yang Shanshan Wu Yuan Zhang Linong Ji Siyan Zhan |
| author_sort | Feng Sun |
| collection | DOAJ |
| description | To evaluate the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on weight reduction in patients with Type 2 diabetes mellitus (Type 2 DM), a network meta-analysis was conducted. MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov were searched from 1950 to October 2013. Randomized controlled trials (RCTs) involving GLP-1 RAs were included if they provided information on body weight. A total of 51 RCTs were included and 17521 participants were enrolled. The mean duration of 51 RCTs was 31 weeks. Exenatide 10 μg twice daily (EX10BID) reduced weight compared with exenatide 5 μg twice daily (EX5BID), liraglutide 0.6 mg once daily (LIR0.6QD), liraglutide—1.2 mg once daily (LIR1.2QD), and placebo treatment, with mean differences of −1.07 kg (95% CI: −2.41, −0.02), −2.38 kg (95% CI: −3.71, −1.06), −1.62 kg (95% CI: −2.79, −0.43), and −1.92 kg (95% CI: −2.61, −1.24), respectively. Reductions of weight treated with liraglutide—1.8 mg once daily (LIR1.8QD) reach statistical significance (−1.43 kg (95% CI: −2.73, −0.15)) versus LIR1.2QD and (−0.98 kg (95% CI: −1.94, −0.02)) versus placebo. Network meta-analysis found that EX10BID, LIR1.8QD, and EX2QW obtained a higher proportion of patients with weight loss than other traditional hypoglycemic agents. Our results suggest GLP-1 RAs are promising candidates for weight control in comparison with traditional hypoglycemic drugs, and EX10BID, LIR1.8QD, and EX2QW rank the top three drugs. |
| format | Article |
| id | doaj-art-a12ef9637bb6484c9b1e9c7ee9cfc5b3 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-a12ef9637bb6484c9b1e9c7ee9cfc5b32025-02-03T06:01:37ZengWileyJournal of Diabetes Research2314-67452314-67532015-01-01201510.1155/2015/157201157201Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisFeng Sun0Sanbao Chai1Lishi Li2Kai Yu3Zhirong Yang4Shanshan Wu5Yuan Zhang6Linong Ji7Siyan Zhan8Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, ChinaDepartment of Physiology, Capital Medical University, Beijing 100069, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, ChinaDepartment of Orthopedics, Tianjin Fifth Central Hospital, Tianjin 300450, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, ChinaDepartment of Endocrinology and Metabolism, People’s Hospital, Peking University, Beijing 100044, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, ChinaTo evaluate the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on weight reduction in patients with Type 2 diabetes mellitus (Type 2 DM), a network meta-analysis was conducted. MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov were searched from 1950 to October 2013. Randomized controlled trials (RCTs) involving GLP-1 RAs were included if they provided information on body weight. A total of 51 RCTs were included and 17521 participants were enrolled. The mean duration of 51 RCTs was 31 weeks. Exenatide 10 μg twice daily (EX10BID) reduced weight compared with exenatide 5 μg twice daily (EX5BID), liraglutide 0.6 mg once daily (LIR0.6QD), liraglutide—1.2 mg once daily (LIR1.2QD), and placebo treatment, with mean differences of −1.07 kg (95% CI: −2.41, −0.02), −2.38 kg (95% CI: −3.71, −1.06), −1.62 kg (95% CI: −2.79, −0.43), and −1.92 kg (95% CI: −2.61, −1.24), respectively. Reductions of weight treated with liraglutide—1.8 mg once daily (LIR1.8QD) reach statistical significance (−1.43 kg (95% CI: −2.73, −0.15)) versus LIR1.2QD and (−0.98 kg (95% CI: −1.94, −0.02)) versus placebo. Network meta-analysis found that EX10BID, LIR1.8QD, and EX2QW obtained a higher proportion of patients with weight loss than other traditional hypoglycemic agents. Our results suggest GLP-1 RAs are promising candidates for weight control in comparison with traditional hypoglycemic drugs, and EX10BID, LIR1.8QD, and EX2QW rank the top three drugs.http://dx.doi.org/10.1155/2015/157201 |
| spellingShingle | Feng Sun Sanbao Chai Lishi Li Kai Yu Zhirong Yang Shanshan Wu Yuan Zhang Linong Ji Siyan Zhan Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis Journal of Diabetes Research |
| title | Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis |
| title_full | Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis |
| title_fullStr | Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis |
| title_full_unstemmed | Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis |
| title_short | Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis |
| title_sort | effects of glucagon like peptide 1 receptor agonists on weight loss in patients with type 2 diabetes a systematic review and network meta analysis |
| url | http://dx.doi.org/10.1155/2015/157201 |
| work_keys_str_mv | AT fengsun effectsofglucagonlikepeptide1receptoragonistsonweightlossinpatientswithtype2diabetesasystematicreviewandnetworkmetaanalysis AT sanbaochai effectsofglucagonlikepeptide1receptoragonistsonweightlossinpatientswithtype2diabetesasystematicreviewandnetworkmetaanalysis AT lishili effectsofglucagonlikepeptide1receptoragonistsonweightlossinpatientswithtype2diabetesasystematicreviewandnetworkmetaanalysis AT kaiyu effectsofglucagonlikepeptide1receptoragonistsonweightlossinpatientswithtype2diabetesasystematicreviewandnetworkmetaanalysis AT zhirongyang effectsofglucagonlikepeptide1receptoragonistsonweightlossinpatientswithtype2diabetesasystematicreviewandnetworkmetaanalysis AT shanshanwu effectsofglucagonlikepeptide1receptoragonistsonweightlossinpatientswithtype2diabetesasystematicreviewandnetworkmetaanalysis AT yuanzhang effectsofglucagonlikepeptide1receptoragonistsonweightlossinpatientswithtype2diabetesasystematicreviewandnetworkmetaanalysis AT linongji effectsofglucagonlikepeptide1receptoragonistsonweightlossinpatientswithtype2diabetesasystematicreviewandnetworkmetaanalysis AT siyanzhan effectsofglucagonlikepeptide1receptoragonistsonweightlossinpatientswithtype2diabetesasystematicreviewandnetworkmetaanalysis |